116,483 Oruka (ORKA) shares distributed to director from LLC

Rhea-AI Filing Summary

Oruka Therapeutics director Carl Dambkowski reported receiving 116,483 shares of common stock on January 23, 2026. The Form 4 shows the shares were acquired at a price of $0.00 through a transaction coded "J," which the footnote explains as a pro-rata distribution from a limited liability company in which he is a member. After this distribution, he beneficially owns 116,483 shares of Oruka common stock in direct form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		J(1)		116,483	A	$0	116,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member.

	/s/ Paul Quinlan, as attorney-in-fact for Carl Dambkowski	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oruka Therapeutics (ORKA) report for Carl Dambkowski?

On January 23, 2026, director Carl Dambkowski reported acquiring 116,483 shares of Oruka Therapeutics common stock in a transaction coded "J."

How many Oruka Therapeutics (ORKA) shares does Carl Dambkowski own after this transaction?

Following the reported transaction, 116,483 shares of Oruka Therapeutics common stock are listed as beneficially owned by Carl Dambkowski.

What does the footnote say about the 116,483 Oruka (ORKA) shares received by Carl Dambkowski?

The footnote states the 116,483 shares represent a pro-rata distribution of common stock for no consideration from a limited liability company in which he is a member.

Did Carl Dambkowski pay anything for the Oruka Therapeutics (ORKA) shares he acquired?

No. The Form 4 lists a price of $0.00 per share, and the footnote explains the shares were received as a pro-rata distribution for no consideration.

Is the Oruka Therapeutics (ORKA) stock held by Carl Dambkowski direct or indirect ownership?

The Form 4 indicates that the 116,483 shares are held with direct (D) ownership following the reported transaction.

What is transaction code "J" in Carl Dambkowski’s Oruka (ORKA) Form 4 filing?

Transaction code "J" is used for other acquisition or disposition types; here it is described as a pro-rata distribution from a limited liability company.